Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660

Article  PubMed  Google Scholar 

Planchard D, Popat S, Kerr K et al (2018) Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(Suppl 4):iv192–iv237. https://doi.org/10.1093/annonc/mdy275

Akamatsu H, Ninomiya K, Kenmotsu H et al (2019) The Japanese Lung Cancer Society guideline for non-small cell lung cancer, stage IV. Int J Clin Oncol 24(7):731–770. https://doi.org/10.1007/s10147-019-01431-z

Article  PubMed  PubMed Central  Google Scholar 

Singh N, Temin S, Baker S Jr et al (2022) Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO living guideline. J Clin Oncol 40(28):3310–3322. https://doi.org/10.1200/JCO.22.00824

Article  PubMed  CAS  Google Scholar 

Singh N, Temin S, Baker S Jr et al (2022) Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO living guideline. J Clin Oncol 40(28):3323–3343. https://doi.org/10.1200/JCO.22.00825

Article  PubMed  CAS  Google Scholar 

Soda M, Choi YL, Enomoto M et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448(7153):561–566. https://doi.org/10.1038/nature05945

Article  PubMed  CAS  Google Scholar 

Gainor JF, Varghese AM, Ou SH et al (2013) ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res 19(15):4273–4281. https://doi.org/10.1158/1078-0432.CCR-13-0318

Article  PubMed  CAS  Google Scholar 

Saito M, Shiraishi K, Kunitoh H et al (2016) Gene aberrations for precision medicine against lung adenocarcinoma. Cancer Sci 107(6):713–720. https://doi.org/10.1111/cas.12941

Article  PubMed  PubMed Central  CAS  Google Scholar 

Shaw AT, Kim DW, Nakagawa K et al (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368(25):2385–2394. https://doi.org/10.1056/NEJMoa1214886

Article  PubMed  CAS  Google Scholar 

Hida T, Nokihara H, Kondo M et al (2017) Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet 390(10089):29–39. https://doi.org/10.1016/S0140-6736(17)30565-2

Article  PubMed  CAS  Google Scholar 

Peters S, Camidge DR, Shaw AT et al (2017) Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 377(9):829–838. https://doi.org/10.1056/NEJMoa1704795

Article  PubMed  CAS  Google Scholar 

Camidge DR, Kim HR, Ahn MJ et al (2018) Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med 379(21):2027–2039. https://doi.org/10.1056/NEJMoa1810171

Article  PubMed  CAS  Google Scholar 

Shaw AT, Bauer TM, de Marinis F et al (2020) First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med 383(21):2018–2029. https://doi.org/10.1056/NEJMoa2027187

Article  PubMed  CAS  Google Scholar 

Kalemkerian GP, Narula N, Kennedy EB et al (2018) Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. J Clin Oncol 36(9):911–919. https://doi.org/10.1200/JCO.2017.76.7293

Article  PubMed  CAS  Google Scholar 

Canterbury CR, Fernandes H, Crapanzano JP et al (2021) ALK gene rearrangements in lung adenocarcinomas: concordance of immunohistochemistry, fluorescence in situ hybridization, RNA in situ hybridization, and RNA next-generation sequencing testing. JTO Clin Res Rep 2(10):100223. https://doi.org/10.1016/j.jtocrr.2021.100223

Article  PubMed  PubMed Central  Google Scholar 

Ariyasu R, Uchibori K, Ninomiya H et al (2021) Feasibility of next-generation sequencing test for patients with advanced NSCLC in clinical practice. Thorac Cancer 12(4):504–511. https://doi.org/10.1111/1759-7714.13786

Article  PubMed  CAS  Google Scholar 

Sun JM, Choi YL, Won JK et al (2012) A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK. J Thorac Oncol 7(12):e36–e38. https://doi.org/10.1097/JTO.0b013e318274694e

Article  PubMed  Google Scholar 

Peled N, Palmer G, Hirsch FR et al (2012) Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. J Thorac Oncol 7(9):e14-16. https://doi.org/10.1097/JTO.0b013e3182614ab5

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ren S, Hirsch FR, Varella-Garcia M et al (2014) Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer. J Thorac Oncol 9(3):e21-23. https://doi.org/10.1097/JTO.0000000000000013

Article  PubMed  PubMed Central  Google Scholar 

Takeuchi K, Togashi Y, Kamihara Y et al (2016) Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study). Ann Oncol 27(1):185–192. https://doi.org/10.1093/annonc/mdv501

Article  PubMed  CAS  Google Scholar 

Ma D, Wang Z, Yang L et al (2016) Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative. Oncotarget 7(39):64410–64420. https://doi.org/10.18632/oncotarget.10560

Article  PubMed  PubMed Central  Google Scholar 

Lin C, Shi X, Yang S et al (2019) Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer. Lung Cancer 131:62–68. https://doi.org/10.1016/j.lungcan.2019.03.018

Article  PubMed  Google Scholar